News
TM3 THERAPEUTICS PUBLISHED IN VIVO PROOF OF CONCEPT DATA FOR TREATMENT OF PKAN
13.09.2017 TM3 Therapeutics, a spin-off of ACIES BIO, is a biopharmaceutical company [...]
Innovation potential and competences grant received
06.07.2017 Within the public call
»Enhancing innovation potential and competences in [...]
ACIES BIO RECEIVES THE JESENKO AWARD FOR OUTSTANDING R&D WORK IN BIOTECHNOLOGY
16.03.2017 Acies Bio received the “Jesenko Award” from Biotechnical Faculty of [...]
ORPHAN DRUG DESIGNATION BY EMA FOR CAB 1803 FOR PKAN TREATMENT
17.06.2016 European Medicines Agency (EMA) granted orphan medicinal product [...]
ACIES BIO RECEIVES A H2020 – SME INST GRANT FROM THE EUROPEAN UNION
15.01.2016 Whey2Value technology has been awarded a substantial grant from EU Horizon [...]
ACIES BIO COLLABORATES IN NEW GENERATION ANTIBIOTICS DEVELOPMENT
04.05.2015 Antimicrobial resistance and the shortage of novel antibiotics have led to [...]
PARTICIPATION IN DEVELOPMENT OF AMINOGLYCOSIDES WITH NO OTOTOXIC SIDE EFFECTS
05.01.2015 Within the TRIH grant scheme (Translational Research Initiative for [...]
DEVELOPMENT OF ABCLONE – PLATFORM FOR CLONING VERY LARGE DNA FRAGMENTS
25.09.2014 ACIES BIO developed a highly efficient one-step in vivo recombinational [...]
ACIES BIO PRESENTS DISRUPTIVE INNOVATION IN WHEY-WASTE MANAGEMENT
22.08.2014 Scientists at Acies Bio developed innovative technology to address a major [...]